Thalidomide-O-amido-C4-NH2 (TFA)

• UNSPSC Description:

  Thalidomide-O-amido-C4-NH2 TFA (Cereblon Ligand-Linker Conjugates 6 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

• Target Antigen:

  Apoptosis; Autophagy; E3 Ligase Ligand-Linker Conjugates

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Autophagy;PROTAC

• Field of Research:

  Others

• Assay Protocol:

  https://www.medchemexpress.com/E3_ligase_Ligand-Linker_Conjugates_16.html

• Purity:

  99.92

• Solubility:

  DMSO : 42.86 mg/mL (ultrasonic)

• Smiles:

  NCCCCNC(COC1=C(C(N2C(CCC3=O)C(N3)=O)=O)C(C2=O)=CC=C1)=O.FC(F)(F)C(O)=O

• Molecular Weight:

  516.42

• References & Citations:

  [1]Zhou B, et al. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins withPicomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem. 2017 Mar 24.|[2]James Bradner, et al. Methods to induce targeted protein degradation through bifunctional molecules. WO 2017024317 A2.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, stored under nitrogen)

• Clinical Information:

  No Development Reported

• CAS Number:

  1799711-25-3